Publicaciones en las que colabora con RAMON SOTO OTERO (20)

2023

  1. Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers

    Antioxidants, Vol. 12, Núm. 4

  2. Implications of Inflammatory and Oxidative Stress Markers in the Attenuation of Nocturnal Blood Pressure Dipping

    Journal of Clinical Medicine, Vol. 12, Núm. 4

2022

  1. Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential prognostic implications in the medium and long term

    PloS one, Vol. 17, Núm. 10, pp. e0268871

  2. Correlation between Blunted Nocturnal Decrease in Diastolic Blood Pressure and Oxidative Stress: An Observational Study

    Antioxidants, Vol. 11, Núm. 12

2017

  1. Effects of Aluminium on Rat Brain Mitochondria Bioenergetics: an In vitro and In vivo Study

    Molecular Neurobiology, Vol. 54, Núm. 1, pp. 563-570

2013

  1. A simple method for isolating rat brain mitochondria with high metabolic activity: Effects of EDTA and EGTA

    Journal of Neuroscience Methods, Vol. 213, Núm. 1, pp. 39-42

2012

  1. 2-Benzazepine nitrones protect dopaminergic neurons against 6-hydroxydopamine-induced oxidative toxicity

    Archiv der Pharmazie, Vol. 345, Núm. 8, pp. 598-609

  2. Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: Protective role of catalase and superoxide dismutase

    Neurochemical Research, Vol. 37, Núm. 10, pp. 2150-2160

2009

  1. Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: Potential effects in a 6-OHDA-induced model of Parkinson's disease

    Journal of Neurochemistry, Vol. 109, Núm. 3, pp. 879-888

2008

  1. Inhibition of 6-hydroxydopamine-induced oxidative damage by 4,5-dihydro-3H-2-benzazepine N-oxides

    Biochemical Pharmacology, Vol. 75, Núm. 7, pp. 1526-1537

2007

  1. Analysis of brain regional distribution of aluminium in rats via oral and intraperitoneal administration

    Journal of Trace Elements in Medicine and Biology, Vol. 21, Núm. SUPPL. 1, pp. 31-34

  2. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons

    Neurobiology of Aging, Vol. 28, Núm. 4, pp. 555-567

  3. Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease

    Neurochemical Research, Vol. 32, Núm. 1, pp. 99-105

2006

  1. Study on the ability of 1,2,3/4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to Parkinson's disease

    Journal of Biochemical and Molecular Toxicology, Vol. 20, Núm. 5, pp. 209-220

2004

  1. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: Role of ferrous and ferric ions

    Neurochemistry International, Vol. 45, Núm. 1, pp. 103-116

2002

  1. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: Relevance for Parkinson's disease

    Biochemical Pharmacology, Vol. 64, Núm. 1, pp. 125-135

  2. Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: Relevance for the pathogenesis of Parkinson's disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1586, Núm. 2, pp. 155-168

2001

  1. Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: Mediation of antioxidants

    Free Radical Biology and Medicine, Vol. 31, Núm. 8, pp. 986-998

  2. Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals potential implications in relation to oxidative stress

    Life Sciences, Vol. 69, Núm. 8, pp. 879-889

2000

  1. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: Potential implication in relation to the pathogenesis of Parkinson's disease

    Journal of Neurochemistry, Vol. 74, Núm. 4, pp. 1605-1612